Group 1 - The company has adjusted its 2025 annual operating performance forecast to provide investors with a clearer understanding of its business performance and future prospects [1][2] - The adjustment in expected operating income is primarily attributed to the leading position of Baiyueze in the US market and its continued expansion in Europe and other key global markets [3] Group 2 - For the first half of 2025, the company's product revenue reached 17.36 billion RMB, a year-on-year increase of 45.8%, while total operating revenue was 17.52 billion RMB, up 46.0% from the previous year [9] - The net profit attributable to the parent company for the first half of 2025 was 450 million RMB, with total assets at 44.87 billion RMB, an increase of 4.8% from the beginning of the period [9][19] - Baiyueze's global sales totaled 12.53 billion RMB in the first half of 2025, representing a year-on-year growth of 56.2%, with US sales at 8.96 billion RMB, up 51.7% [10][11] Group 3 - Baiyueze is the only BTK inhibitor with flexible dosing options, and it has been approved in 75 markets globally, with ongoing clinical trials in over 30 countries [12] - The company is also advancing its next-generation pipeline products and emphasizes a rapid concept verification strategy in its global clinical development [14] - The company has a significant presence in the oncology research field, with a large team dedicated to small molecule and antibody drug discovery [14] Group 4 - The company has initiated several key clinical trials for its products, including the global phase III trial for Sonrotoclax in combination with Baiyueze for CLL patients [15][16] - The company plans to launch multiple clinical trials for various cancer treatments in the coming years, including trials for breast cancer and lung cancer [17]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeOne Medicines Ltd. 百濟神州有限公司 （根據瑞士法律註冊成立的公司） （股份代號：06160） 海外監管公告 本公告乃百濟神州有限公司（BeOne Medicines Ltd., 「本公司」）根據香港聯合交易 所有限公司證券上市規則第13.10B條作出。 A 股代码：688235 A 股简称：百济神州 公告编号：2025-028 港股代码：06160 港股简称：百济神州 美股代码：ONC 百济神州有限公司 2025年半年度主要财务数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 特别提示： 本公告所载的百济神州有限公司（以下简称"百济神州"或"公司"）2025 年半年度主要财务数据为初步核算数据，未经会计师事务所审计，具体数据以公司 2025 年半年度报告中披露的数据为准，提请投资者注意投 ...

Core Insights - The company reported a significant increase in product revenue for the first half of 2025, reaching 17.36 billion yuan, a year-on-year growth of 45.8% [1] - Total revenue for the same period was 17.52 billion yuan, reflecting a 46.0% increase compared to the previous year [1] - The net profit attributable to the parent company was 450 million yuan [1] Revenue Breakdown - The growth in product revenue was primarily driven by sales of self-developed products such as Baiyueze® (Zebutinib capsules) and licensed products from Amgen, as well as Baizean® (Tislelizumab injection) [2] - Baiyueze® achieved global sales of 12.53 billion yuan, marking a 56.2% year-on-year increase, with U.S. sales contributing 8.96 billion yuan, up 51.7% [2] - European sales of Baiyueze® totaled 1.92 billion yuan, a significant increase of 81.4%, while sales in China reached 1.19 billion yuan, growing by 36.5% [2] Product Performance - Baizean® recorded sales of 2.64 billion yuan, a 20.6% increase, driven by new indications approved for reimbursement in China [3] - Baiyueze® is noted for having the broadest range of approved indications among BTK inhibitors globally and is the only one with flexible dosing options [3] - The company has conducted over 35 clinical trials involving approximately 7,100 patients for Baiyueze®, which is now approved in 75 markets worldwide [3] R&D and Future Prospects - The company is advancing its next-generation self-developed pipeline products with a focus on rapid early clinical concept validation [4] - The global R&D team consists of over 3,700 personnel, collaborating with regulatory bodies and researchers across more than 45 countries [4] - The company anticipates over 20 milestone advancements in its hematological and solid tumor pipelines within the next 18 months [4]

Core Viewpoint - Moderna is facing significant financial challenges due to declining sales of its COVID-19 vaccines, leading to a 10% workforce reduction and a stock price drop of over 75% in the past year [3][4]. Group 1: Financial Performance - Moderna announced a workforce reduction of nearly 1,000 employees, aiming to reduce its total staff to approximately 5,000 by the end of the year due to ongoing sales declines [3]. - The company's market capitalization has plummeted from nearly $200 billion at the peak of the pandemic to about $11 billion currently [3]. - Moderna plans to cut annual operating expenses by approximately $1.5 billion by 2027 [3]. Group 2: Product Development and Strategy - Despite the ongoing challenges, Moderna remains committed to developing new COVID-19 vaccines, with the FDA recently approving its third vaccine targeting new variants [3]. - The company has the potential to launch up to eight new products in the next three years [3]. - In contrast, BioNTech has successfully diversified its product pipeline and adjusted its strategy post-pandemic, leading to a stock price increase of nearly 25% over the past year and a market cap exceeding $25 billion [4][5]. Group 3: Market Comparison - BioNTech's strategy includes investing in licensing deals and diversifying into emerging fields like antibody-drug conjugates (ADCs), which has garnered investor confidence [4][5]. - Moderna's reliance on vaccine sales and its delayed product diversification strategy has raised concerns among investors about its long-term viability [5].

Group 1 - The core viewpoint of the article indicates skepticism from the capital market regarding Moderna's business strategy, particularly concerning the rebound in sales of COVID-19 and RSV vaccines [1][2] - Moderna announced a global workforce reduction of 10%, cutting nearly 1,000 employees to approximately 5,000 by the end of the year due to declining sales of COVID-19 vaccines, leading to an over 8% drop in stock price after hours on July 31 [1] - The company's financial crisis has worsened, with its stock price falling over 75% in the past year, and its market capitalization plummeting from nearly $200 billion at the peak of the pandemic to about $11 billion currently [1] Group 2 - In contrast to Moderna, BioNTech has successfully adjusted its strategy post-pandemic, resulting in a nearly 25% increase in stock price over the past year and a market capitalization exceeding $25 billion, more than double that of Moderna [2][3] - BioNTech has focused on diversifying its portfolio and entering new markets, such as the emerging ADC (antibody-drug conjugate) field, while also securing a potential $11 billion deal with Bristol-Myers Squibb for developing dual antibody drugs [3] - A biopharmaceutical investor noted that Moderna missed the opportunity to diversify its product offerings using the substantial revenue generated from COVID-19 vaccines, suggesting that more product licensing could have led to a more favorable perception in the capital market [3]

Group 1 - The capital market's reaction indicates skepticism towards Moderna's business strategy, with investors lacking confidence in the rebound of sales for COVID-19 and RSV vaccines [1][2] - Moderna announced a 10% global workforce reduction, cutting nearly 1,000 employees due to declining COVID-19 vaccine sales, leading to an over 8% drop in stock price [1] - The company's stock has fallen over 75% in the past year, with its market capitalization plummeting from nearly $200 billion at the pandemic peak to approximately $11 billion currently [1] Group 2 - In contrast, BioNTech has adjusted its strategy post-pandemic, resulting in a nearly 25% increase in stock price over the past year and a market capitalization exceeding $25 billion, more than double that of Moderna [2][3] - BioNTech has diversified its investments, focusing on licensing deals and entering the emerging ADC (antibody-drug conjugate) market, while Moderna has heavily invested in mRNA vaccine development [3] - BioNTech recently secured a potential $11 billion deal with Bristol-Myers Squibb for a dual antibody drug, which was acquired from a Chinese biotech company for less than $1 billion [3]

Core Viewpoint - Maiwei Biotech (688062.SH) has received regulatory approvals for its innovative antibody-drug conjugate (ADC) 7MW4911, marking a significant step in its clinical development [1] Group 1: Regulatory Approvals - The company has received a formal acceptance notice from the National Medical Products Administration (NMPA) for the clinical trial application of 7MW4911 [1] - The U.S. Food and Drug Administration (FDA) has issued an IND Acknowledgement Letter confirming receipt of the IND application for 7MW4911 [1] Group 2: Product Overview - 7MW4911 is developed based on the company's proprietary IDDC? antibody conjugate technology platform, targeting cadherin-17 (CDH17) [1] - CDH17 is identified as a potential therapeutic target validated by multi-omics in various cancers, particularly overexpressed in colorectal, gastric, and pancreatic cancers, which are associated with tumor invasion and poor prognosis [1] Group 3: Mechanism and Design - The ADC features a highly engineered design that integrates three core components: a high-specificity monoclonal antibody Mab0727, a novel cleavable linker, and a proprietary DNA topoisomerase I inhibitor MF-6 [1] - MF-6 is designed to overcome multidrug resistance mechanisms, enhancing antitumor activity through excellent plasma stability, controllable drug release, and a strong bystander effect [1]

Core Viewpoint - Maiwei Biotech (688062.SH) has received regulatory approvals for its innovative antibody-drug conjugate (ADC) 7MW4911, marking a significant step in its clinical development [1] Regulatory Approvals - The company has received a formal acceptance notice from the National Medical Products Administration (NMPA) for the clinical trial application of 7MW4911 [1] - Additionally, the U.S. Food and Drug Administration (FDA) has issued an IND Acknowledgement Letter confirming receipt of the IND application for 7MW4911 [1] Product Development - 7MW4911 is developed based on the company's proprietary IDDC? antibody conjugate technology platform, targeting cadherin-17 (CDH17) [1] - CDH17 is identified as a promising therapeutic target validated by multi-omics across various cancer types, with significant overexpression in colorectal, gastric, and pancreatic cancers [1] - The design of 7MW4911 integrates three core components: a high-specificity monoclonal antibody Mab0727, a novel cleavable linker, and a proprietary DNA topoisomerase I inhibitor MF-6 [1] Mechanism of Action - MF-6 is designed to overcome multi-drug resistance mechanisms, enhancing anti-tumor activity through excellent plasma stability, controllable drug release, and a strong bystander effect [1]

Core Viewpoint - The company has received formal acceptance of its clinical trial application for the injectable 7MW4911 from the National Medical Products Administration, indicating progress in its development of a novel antibody-drug conjugate targeting CDH17, which is overexpressed in various gastrointestinal cancers [1] Group 1: Clinical Development - The injectable 7MW4911's clinical trial application has been officially accepted by the National Medical Products Administration [1] - The U.S. Food and Drug Administration has acknowledged receipt of the IND application for 7MW4911 [1] Group 2: Product Details - 7MW4911 is developed based on the company's proprietary IDDC antibody-drug conjugate technology platform [1] - The drug targets calcium adhesion protein 17 (CDH17), which is significantly overexpressed in colorectal, gastric, and pancreatic cancers [1] - The high expression of CDH17 is closely related to tumor invasion, metastasis, and poor prognosis [1] Group 3: Therapeutic Potential - 7MW4911 demonstrates the potential to be a transformative therapy for advanced gastrointestinal solid tumors through CDH17-mediated selective cytotoxic payload release [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 自願公告 JSKN003獲美國FDA批准開展一項治療不限HER2表達水平的 PROC的II期臨床研究 本公告乃由康寧傑瑞生物製藥（「本公司」，連同其附屬公司統稱「本集團」）自願作 出，以知會本集團股東（「股東」）及潛在投資者有關本集團之最新業務進展。 本公司董事（「董事」）會（「董事會」）欣然宣佈，JSKN003已獲美國（「美國」）食 品藥品監督管理局（「FDA」）批准，在美國開展一項I I期臨床研究（研究編號： JSKN003-202）。JSKN003-202是JSKN003的一項隨機、開放式標籤、多中心的 II期臨床研究，用於治療鉑耐藥復發性上皮性卵巢癌、原發性腹膜癌或輸卵管癌 （統稱為鉑耐藥卵巢癌，「PROC」），且不限人表皮生長因子受體2（「HER2」）表達 水平。此臨床試驗旨在評估JSKN003在上述人群中的療效和安全性，並確定推薦 III期劑量。此次JSKN003-202獲美國FDA批准，是 ...